E.g., 03/30/2024
E.g., 03/30/2024

FDA Clears bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU

18 October, 2007

bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® B·R·A·H·M·S PCT®. The test will be used with critically ill patients on their first day of admission to the Intensive Care Unit (ICU) as an aid to assess their risk for progression to severe sepsis and septic shock.

bioMérieux Launches VIDAS® NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure

01 October, 2007

bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.

Early Diagnosis of Sepsis: bioMérieux presents new Sepsis Handbook at International Sepsis Forum

26 September, 2007

bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of the “Sepsis Handbook”. This comprehensive book, produced by bioMérieux Editions, will be presented in a special preview at the International Sepsis Forum (ISF) held in Paris (Institut Pasteur), September 26-29, 2007.

bioMérieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment

17 September, 2007

bioMérieux and Ipsen announce today that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.

Settlement between bioMérieux and Becton, Dickinson in the Field of Methicillin-resistant Staphylococcus aureus (MRSA) Detection

08 August, 2007

bioMérieux S.A. (Euronext: BIM) announced today that it has concluded a settlement on several licence agreements with GeneOhm Sciences Canada, a subsidiary of Becton, Dickinson and Company, in the field of Methicillin-resistant Staphylococcus aureus (MRSA) detection. This settlement, whose financial terms are confidential, follows arbitration proceedings that bioMérieux initiated against GeneOhm Sciences Canada in April 2007. Stéphane Bancel, Chief Executive Officer of bioMérieux, stated: “This settlement confirms the relevance of the intellectual property rights held by bioMérieux in this field. bioMérieux intends to play a major role in protecting patients from healthcare-associated infections, among which Methicillin-resistant Staphylococcus aureus (MRSA) are of critical concern for hospital clinicians.”

bioMérieux launches the first automated detection test for Clostridium difficile A and B toxins

24 July, 2007

A new, rapid, and effective solution in the fight against hospital-acquired (nosocomial)infections. bioMérieux, a world leader in the field of in vitro diagnostics, (Euronext : BIM) has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe.

Pioneering Diagnostics